Indeed, the STING agonists, TAK-676 (NCT04420884, NCT04879849) and E7766 (NCT04144140), are currently being tested clinically for the treatment of advanced or metastatic solid tumors, lymphomas, and leukemias, as adjunctive agents to conventional chemotherapy. The gene discussed is STING1; the disease is lymphoma.